Memorial Hospital Research Laboratories

The Martin Weiser Lab

Research

Pictured: Martin R. Weiser
Martin R. Weiser, MD

Our research investigates the natural history, molecular biology, and treatment response of cancers of the rectum and colon with the goal of personalizing therapy to reduce treatment toxicity, increase survival, and improve post-treatment quality of life.  We have built and tested clinical calculators using clinical, pathologic and molecular features to improve prognostication and better understand tumor biology.  Our contributions to advancing our understanding of colorectal cancer biology and improving colorectal cancer treatment include refinement of neoadjuvant chemotherapy with selective use of radiotherapy, identification of constitutive activation of receptor tyrosine kinases, and characterization of drivers of tumor-infiltrating lymphocytes. 

Publications Highlights

Kim JK, Chen CT, Keshinro A, Khan A, Firat C, Vanderbilt C, Segal N, Stadler Z, Shia J, Balachandran VP, Weiser MR. 2022. Intratumoral T-cell repertoires in DNA mismatch repair-proficient and -deficient colon tumors containing high or low numbers of tumor-infiltrating lymphocytes. OncoImmunology 11:e2054757.

Weiser MR, Hsu M, Bauer PS, Chapman WC Jr., Gonzalez I,  Chatterjee D, Lingam D, Mutch MG, Keshinro A, Shia J, Vakiani E, Konishi T, Shimada Y, Stadler Z, Segal NH, Cercek A, Saltz L, Yaeger R, Varghese A,  Widmar M, Wei IH, Pappou EP, Smith JJ, Nash G, Paty P, Garcia-Aguilar J, Gonen M. 2021. Clinical calculator based on molecular and clinicopathologic characteristics predicts recurrence following resection of stage I-III colon cancer. J. Clin. Oncol. 39:911–919.

Weiser MR, Chou JF, Keshinro A, Chapman W, Bauer PS, Mutch MG, Parikh PJ, Cercek A, Saltz LB, Gollub MJ, Romesser PB, Crane CH, Shia J, Markowitz AJ, Garcia-Aguilar J, Gonen M, Colorectal Cancer Disease Management Team of Memorial Sloan Kettering Cancer Center. 2021. Development and assessment of a clinical calculator for estimating the likelihood of recurrence and survival among patients with locally advanced rectal cancer treated with chemotherapy, radiotherapy, and surgery. JAMA Netw. Open 4:e2133457.

Keshinro A, Vanderbilt C, Kim JK, Firat C, Chen CT, Yaeger R, Ganesh K, Segal NH, Gonen M, Shia J, Stadler Z, Weiser MR. 2021. Tumor-infiltrating lymphocytes, tumor mutational burden, and genetic alterations in microsatellite unstable, microsatellite stable, or mutant POLE/POLD1 colon cancer. JCO Precis. Oncol. 5:817–826.

Jimenez-Rodriguez RM, Patil S, Keshinro A, Shia J, Vakiani E, Stadler Z, Segal NH, Yaeger R, Konishi T, Shimada Y, Widmar M, Wei I, Pappou E, Smith JJ, Nash G, Paty P, Garcia-Aguilar J, Weiser MR. 2020. Quantitative assessment of tumor-infiltrating lymphocytes in mismatch repair proficient colon cancer. OncoImmunology 9:1841948.

View All Publications

People

Pictured: Martin R. Weiser

Martin R. Weiser, MD

  • Physician-scientist Martin Weiser investigates the mechanisms underlying tumor spread and metastasis and how these mechanisms could be targeted.
View physician profile
Physician profile

Members

Tommy Chen

Senior Research Technician

Asama Khan

Research Fellow

Lab Affiliations

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Martin R. Weiser discloses the following relationships and financial interests:

  • UptoDate
    Intellectual Property Rights; Professional Services and Activities

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.


This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures